Revolution Medicines priced a large concurrent offering—its follow-on stock and debt raise totaling $2 billion—just days after topline Phase 3 results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The company’s financing underscores market appetite after investors reacted to reported survival gains versus chemotherapy. Revolution Medicines’ strategy relies on daraxonrasib’s RAS-mutant targeting approach, positioning the drug for potential regulatory advancement through a fast-track pathway. The financing is also expected to support continued development as the company prepares data submissions. The size of the raise highlights the continued ability of oncology-focused biotechs with late-stage catalysts to access public markets even as funding conditions remain uneven across the sector.